While the issue has fallen from the headlines after several moves to cap the cost, some patients with diabetes still often ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Indianapolis-based drugmaker Eli Lilly and Company has announced price reductions of 70% for its most commonly prescribed insulins, as well as expansion of its Insulin Value Program, capping ...

The US Food and Drug Administration (FDA) has approved Sanofi’s Merilog (insulin-aspart-szjj), a biosimilar to Novolog ...

Novo Nordisk agreed to cap insulin prices to settle a lawsuit in which Minnesota's attorney general accused the three largest insulin makers of charging astronomically high prices for the diabetes ...

Lilly's arch-rival in the diabetes category Novo Nordisk is working on its own glucose-sending insulin platform, acquired via its $800 million acquisition of UK biotech Ziylo in 2018.

Merilog’s approval comes as the insulin space has over the past year suffered several setbacks, including strong calls for ...

All the company’s insulin products will be capped for both insured and uninsured customers with prescriptions. Last February, Ellison announced a settlement with Eli Lilly capping prices at $35 ...

If California patients pay more than $35 per month for insulin now, it’s in large part because PBMs have rigged the system in ...

Six years ago, the average monthly out-of-pocket cost for insulin made by Eli Lilly was $38.64. It’s now $17.16, a 56% drop. In other words, insulin manufacturers have been dropping their prices ...